AAC Holdings, Inc. provides inpatient and outpatient substance use treatment services for individuals with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues in the United States. Its therapy services include motivational interviewing, cognitive behavioral therapy, rational emotive behavior therapy, dialectical behavioral therapy, solution-focused therapy, eye movement desensitization and reprocessing, and systematic family intervention. As of June 30, 2018, the company operated 11 inpatient substance abuse treatment facilities, focused on delivering clinical care and treatment solutions across 1,112 inpatient beds, including 732 licensed detoxification beds, 26 standalone outpatient centers, and 5 sober living facilities across 409 beds for a total of 1,521 combined inpatient and sober living beds. It also offers Internet marketing services to families and individuals struggling with addiction and seeking treatment options through online directories of treatment providers, treatment provider reviews, forums, and professional communities; and online marketing solutions to other treatment providers, such as facility profiles, audience targeting, lead generation, and tools for digital reputation management. In addition, the company performs drug testing and diagnostic laboratory services; and provides physician services to its clients. AAC Holdings, Inc. was founded in 2014 and is headquartered in Brentwood, Tennessee.
Industry, Sector and Symbol
Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone615-732-1231
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$317.64 million
Profitability
Miscellaneous
Employees2,100
OptionableOptionable
AAC (NYSE:AAC) Frequently Asked Questions
What is AAC's stock symbol?
AAC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AAC."
How were AAC's earnings last quarter?
AAC Holdings Inc (NYSE:AAC) released its earnings results on Tuesday, November, 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by $0.32. The firm had revenue of $77.47 million for the quarter, compared to analyst estimates of $84.21 million. AAC had a negative net margin of 10.20% and a positive return on equity of 4.21%. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 EPS. View AAC's Earnings History.
When is AAC's next earnings date?
What guidance has AAC issued on next quarter's earnings?
AAC updated its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $-0.15--0.1 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.72. The company issued revenue guidance of $315-320 million, compared to the consensus revenue estimate of $337.24 million.AAC also updated its FY18 guidance to ($0.15-0.10) EPS.
What price target have analysts set for AAC?
2 equities research analysts have issued 12-month price objectives for AAC's shares. Their predictions range from $4.00 to $12.00. On average, they expect AAC's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price. View Analyst Price Targets for AAC.
What is the consensus analysts' recommendation for AAC?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AAC.
What are Wall Street analysts saying about AAC stock?
Here are some recent quotes from research analysts about AAC stock:
- 1. According to Zacks Investment Research, "AAC Holdings, Inc. is a provider of inpatient substance abuse treatment services for individuals with drug and alcohol addiction. It provides detoxification, residential treatment, partial hospitalization, and intensive outpatient care services. AAC Holdings, Inc. is headquartered in Brentwood, Tennessee. " (1/23/2019)
- 2. Cantor Fitzgerald analysts commented, "1Q18 results were ahead of consensus on both the top and bottom lines, although consensus is comprised of only three estimates. Results were boosted by the AdCare acquisition (closed March 1), but we expect more earnings impact from AdCare in 2Q18 and beyond." (5/2/2018)
Has AAC been receiving favorable news coverage?
Media headlines about AAC stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AAC earned a news impact score of 2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next few days.
Who are some of AAC's key competitors?
Some companies that are related to AAC include RTI Surgical (RTIX), TapImmune (MRKR), Catalyst Pharmaceuticals (CPRX), Voyager Therapeutics (VYGR), Verrica Pharmaceuticals (VRCA), Genesis Healthcare (GEN), Eiger Biopharmaceuticals (EIGR), Gamida Cell (GMDA), Urovant Sciences (UROV), Aclaris Therapeutics (ACRS), Savara (SVRA), Taxus Pharmaceuticals (TXSP), Verastem (VSTM), Neuronetics (STIM) and Pulse Biosciences (PLSE).
Who are AAC's key executives?
AAC's management team includes the folowing people:
- Mr. Michael T. Cartwright, Chairman & CEO (Age 51)
- Dr. Thomas W. Doub, Chief Compliance Officer & Chief Clinical Officer (Age 50)
- Mr. Michael Nanko Ph.D., Pres & COO (Age 63)
- Mr. Andrew W. McWilliams, CFO & Chief Accounting Officer (Age 47)
- Mr. Michael J. Stetar, Chief Technology Officer
Who are AAC's major shareholders?
AAC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.59%). Company insiders that own AAC stock include Darrell S Freeman, David C Kloeppel, Jerrod N Menz, Michael J Blackburn, Michael Nanko, Michael T Cartwright and W Larry Cash. View Institutional Ownership Trends for AAC.
Which institutional investors are buying AAC stock?
AAC stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought AAC stock in the last two years include Darrell S Freeman, Michael Nanko and W Larry Cash. View Insider Buying and Selling for AAC.
How do I buy shares of AAC?
Shares of AAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AAC's stock price today?
One share of AAC stock can currently be purchased for approximately $2.51.
How big of a company is AAC?
AAC has a market capitalization of $61.75 million and generates $317.64 million in revenue each year. The company earns $-20,570,000.00 in net income (profit) each year or $0.60 on an earnings per share basis. AAC employs 2,100 workers across the globe.
What is AAC's official website?
How can I contact AAC?
AAC's mailing address is 200 POWELL PLACE, BRENTWOOD TN, 37027. The company can be reached via phone at 615-732-1231 or via email at [email protected]
MarketBeat Community Rating for AAC (NYSE AAC)
MarketBeat's community ratings are surveys of what our community members think about AAC and other stocks. Vote "Outperform" if you believe AAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
